CIK 0001434316
- Non-accelerated filer
- Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 651311552
- Phone
- +1 858-875-1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-12-13 | Valamehr Bahram Chief R&D Officer | Sale | −1,600 | $49.27 | $79K | 156,698 |
| 2021-12-13 | Valamehr Bahram Chief R&D Officer | Option exercise · Stock Option (Right to Buy) | +25,000 | 61,156 | ||
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Option exercise | +7,500 | $16.32 | $122K | 133,258 |
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Sale | −2,097 | $49.32 | $103K | 131,161 |
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Sale | −900 | $50.42 | $45K | 130,261 |
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Sale | −1,045 | $51.08 | $53K | 129,216 |
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Sale | −1,822 | $52.37 | $95K | 127,394 |
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Sale | −1,031 | $53.66 | $55K | 126,363 |
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Sale | −600 | $54.58 | $33K | 126,763 |
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Sale | −5 | $55.54 | $278 | 125,758 |
| 2021-12-10 | Chu Yu-Waye Senior VP Clinical Development | Option exercise · Stock Option (Right to Buy) | −7,500 | 105,000 | ||
| 2021-11-19 | Wolchko J Scott President and CEO | Grant or award | +86,475 | 480,268 | ||
| 2021-11-19 | Valamehr Bahram Chief R&D Officer | Grant or award | +60,958 | 156,698 | ||
| 2021-11-19 | TAHL CINDY General Counsel and Secretary | Grant or award | +60,958 | 169,006 | ||
| 2021-11-19 | Plavsic Mark Chief Technical Officer | Grant or award | +59,540 | 97,540 | ||
| 2021-11-19 | Dulac Edward J III Chief Financial Officer | Grant or award | +59,540 | 111,944 | ||
| 2021-11-19 | Chu Yu-Waye Senior VP Clinical Development | Grant or award | +60,958 | 125,758 | ||
| 2021-11-18 | Wolchko J Scott President and CEO | Option exercise | +20,000 | $2.70 | $54K | 413,793 |
| 2021-11-18 | Wolchko J Scott President and CEO | Sale | −20,000 | $54.27 | $1.1M | 393,793 |
| 2021-11-18 | Wolchko J Scott President and CEO | Option exercise · Stock Option (right to buy) | −20,000 | 79,446 |
Page 15 of 26 · 503 trades